CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 16 enrolled
Drug / intervention
3K3A-APC Proteindrug
Likely dose
3K3A-APC Protein 15mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05039268
NCT05039268Phase 2Completed
CompareCT.gov

A Phase 2 Open Label Trial of 3K3A-APC in Amyotrophic Lateral Sclerosis

Macquarie University, Australia·interventional·Posted Sep 9, 2021·Updated Oct 11, 2023

In Brief

A Phase 2 clinical trial evaluating 3K3A-APC Protein for Amyotrophic Lateral Sclerosis. Completed, enrolled 16 participants across 1 site.

Detailed Summary

Phase 2 open label trial to investigate the safety and potentially efficacy of 3K3A-APC in patients with Amyotrophic Lateral Sclerosis (ALS).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAmyotrophic Lateral Sclerosis
CountriesAustralia
CollaboratorsZZ Biotech, LLC

Timeline

Phase 2CompletedFinished
20222023202420252026
First PostedSep 9, 2021
Enrollment StartNov 25, 2021
Primary CompletionSep 12, 2022
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 4.8 years ago

Interventions

3K3A-APC Proteindrug

3K3A-APC with intravenous dosing of five doses of either 15mg or 30mg at 12 hourly interval. The first 8 patients will receive 15mg dose, and the next 8 patients will receive 30mg dose.